Patents by Inventor Gary R. Matsueda
Gary R. Matsueda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7189829Abstract: The present invention relates to the isolation and identification of novel baboon nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid molecules, or degenerate variants thereof, which proteins and polypeptides comprise novel baboon thrombin-activatable fibrinolysis inhibitors or “TAFI” enzyme molecules. Because the novel baboon TAFI proteins and polypeptides of the invention inhibit the breakdown of blood clots, they may be therapeutically useful for the treatment of blood disorders wherein clotting needs to be regulated or promoted, such as hemophilia or von Willebrand's disease or in other situations, such as trauma, wherein blood clotting or coagulation needs to be regulated or promoted. The sequences of the invention are also useful in screening methods for the identification of compounds that modulate the expression of the baboon TAFI nucleic acids and/or the activity of the baboon TAFI proteins and polypeptides of the invention.Type: GrantFiled: April 17, 2006Date of Patent: March 13, 2007Assignee: Bristol-Myers Squibb CompanyInventors: James K. Tamura, Gary R. Matsueda, Mei-Yin Hsu
-
Patent number: 7091331Abstract: The present invention relates to the isolation and identification of novel baboon nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid molecules, or degenerate variants thereof, which proteins and polypeptides comprise novel baboon thrombin-activatable fibrinolysis inhibitors or “TAFI” enzyme molecules. Because the novel baboon TAFI proteins and polypeptides of the invention inhibit the breakdown of blood clots, they may be therapeutically useful for the treatment of blood disorders wherein clotting needs to be regulated or promoted, such as hemophilia or von Willebrand's disease or in other situations, such as trauma, wherein blood clotting or coagulation needs to be regulated or promoted. The sequences of the invention are also useful in screening methods for the identification of compounds that modulate the expression of the baboon TAFI nucleic acids and/or the activity of the baboon TAFI proteins and polypeptides of the invention.Type: GrantFiled: March 4, 2003Date of Patent: August 15, 2006Assignee: Bristol-Myers Squibb CompanyInventors: James K. Tamura, Gary R. Matsueda, Mei-Yin Hsu, Akbar Nayeem
-
Publication number: 20030215850Abstract: The present invention relates to the isolation and identification of novel baboon nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid molecules, or degenerate variants thereof, which proteins and polypeptides comprise novel baboon thrombin-activatable fibrinolysis inhibitors or “TAFI” enzyme molecules. Because the novel baboon TAFI proteins and polypeptides of the invention inhibit the breakdown of blood clots, they may be therapeutically useful for the treatment of blood disorders wherein clotting needs to be regulated or promoted, such as hemophilia or von Willebrand's disease or in other situations, such as trauma, wherein blood clotting or coagulation needs to be regulated or promoted. The sequences of the invention are also useful in screening methods for the identification of compounds that modulate the expression of the baboon TAFI nucleic acids and/or the activity of the baboon TAFI proteins and polypeptides of the invention.Type: ApplicationFiled: March 4, 2003Publication date: November 20, 2003Inventors: James K. Tamura, Gary R. Matsueda, Mei-Yin Hsu, Akbar Nayeem
-
Patent number: 6576431Abstract: The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to &agr;2-antiplasmin crosslinked to fibrin (&agr;2AP-FX) which does not inhibit plasma &agr;2-antiplasmin (&agr;2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward &agr;2-antiplasmin crosslinked to fibrin which does not inhibit plasma &agr;2AP together with a thrombolytic agent.Type: GrantFiled: August 16, 2001Date of Patent: June 10, 2003Assignee: The General Hospital CorporationInventors: Guy L. Reed, Edgar Haber, Gary R. Matsueda
-
Publication number: 20020086025Abstract: The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to &agr;2-antiplasmin crosslinked to fibrin (&agr;2AP-FX) which does not inhibit plasma &agr;2-antiplasmin (&agr;2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward &agr;2-antiplasmin crosslinked to fibrin which does not inhibit plasma &agr;2AP together with a thrombolytic agent.Type: ApplicationFiled: August 16, 2001Publication date: July 4, 2002Inventors: Guy L. Reed, Edgar Haber, Gary R. Matsueda
-
Patent number: 6280730Abstract: The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to &agr;2-antiplasmin crosslinked to fibrin (&agr;2AP-FX) which does not inhibit plasma &agr;2-antiplasmin (&agr;2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward &agr;2-antiplasmin crosslinked to fibrin which does not inhibit plasma &agr;2AP together with a thrombolytic agent.Type: GrantFiled: November 24, 1997Date of Patent: August 28, 2001Assignee: The General Hospital CorporationInventors: Guy L. Reed, Edgar Haber, Gary R. Matsueda
-
Patent number: 5831031Abstract: The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to .alpha.2-antiplasmin crosslinked to fibrin (.alpha.2AP-FX) which does not inhibit plasma .alpha.2-antiplasmin (.alpha.2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward .alpha.2-antiplasmin crosslinked to fibrin which does not inhibit plasma .alpha.2AP together with a thrombolytic agent.Type: GrantFiled: July 16, 1996Date of Patent: November 3, 1998Assignee: The General Hospital CorporationInventors: Guy L. Reed, Edgar Haber, Gary R. Matsueda
-
Patent number: 5773228Abstract: The present invention provides a thrombin-activated platelet protein (TAPP). The protein is selectively expressed on the surface of thrombin-activated platelets. Antibodies which selectively bind to the thrombin-activated platelet protein are also provided. These compositions find use in the detection and treatment of blood clots.Type: GrantFiled: June 2, 1995Date of Patent: June 30, 1998Assignee: The General Hospital CorporationInventors: Guy L. Reed, Gary R. Matsueda
-
Patent number: 5620688Abstract: Compositions and methods for inhibiting the activation and/or active state of a precursor protein are provided. Compositions provided can bind to a cleavage site of a precursor protein. Also provided are compounds useful for generating inhibitor compositions. Application of the invention to the treatment of myocardial infarction and other thrombotic conditions is specifically provided. Further provided are antibodies specific for active Factor XIII.Type: GrantFiled: May 4, 1994Date of Patent: April 15, 1997Assignees: Bristol-Myers Squibb Company, General Hospital Corporation, TheInventors: Guy L. Reed, Gary R. Matsueda, Edgar Haber
-
Patent number: 5582862Abstract: The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to .alpha.2-antiplasmin crosslinked to fibrin (.alpha.2AP-Fx) which does not inhibit plasma .alpha.2-antiplasmin (.alpha.2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward .alpha.2-antiplasmin crosslinked to fibrin which does not inhibit plasma .alpha.2AP together with a thrombolytic agent.Type: GrantFiled: December 1, 1992Date of Patent: December 10, 1996Assignee: General Hospital CorporationInventors: Guy L. Reed, Edgar Haber, Gary R. Matsueda
-
Patent number: 5571708Abstract: A new chimeric plasminogen activator with high fibrin affinity was designed to bind to a fibrin clot and initiate clot destruction in the presence of thrombin, but not plasmin. The chimeric molecule has an antibody variable region having a fibrin-specific antigen binding site and a single chain urokinase region having a thrombin activation site but not a plasmin activation site. The preferred embodiment, 59D8-ScuPA-T, has an N-terminal fragment of an anti-fibrin antibody (59DB) and a C-terminal thrombin-activatable low molecular weight single-chain urokinase plasminogen activator (scuPA-T). The scuPA-T portion was obtained by deletion of two amino acids (Phe157 and Lys 158) that make up the plasmin activation site from low molecular weight single chain urokinase-type plasminogen activator (scuPA).Type: GrantFiled: April 19, 1993Date of Patent: November 5, 1996Assignee: Bristol-Myers Squibb CompanyInventors: Wen-Pin Yang, Gary R. Matsueda, Shyh-Yu Shaw
-
Patent number: 5446132Abstract: The present invention provides a thrombin-activated platelet protein (TAPP). The protein is selectively expressed on the surface of thrombin-activated platelets. Antibodies which selectively bind to the thrombin-activated platelet protein are also provided. These compositions find use in the detection and treatment of blood clots.Type: GrantFiled: October 1, 1992Date of Patent: August 29, 1995Assignee: The General Hospital CorporationInventors: Guy L. Reed, Gary R. Matsueda
-
Patent number: 5372812Abstract: The present invention relates to a novel treatment for blood clots within a patient or myocardial infarction which comprises administering a hapten-binding molecule capable of preventing inhibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for blood clots within a patient or myocardial infarction comprising coadministrating the hapten-binding molecule of the invention together with a thrombolytic agent capable of either dissolving fibrin-platelet clots or inhibiting their formation. The therapy of the invention is capable of increasing clot lysis while minimizing fibrinogen breakdown and preventing the reocclusion of the affected coronary artery. The therapy of the present invention is capable of achieving this goal even in the absence of heparin and when the concentration of thrombolytic agent is lower than that required by other potential therapies.Type: GrantFiled: September 10, 1992Date of Patent: December 13, 1994Assignee: The General Hospital CorporationInventors: Guy L. Reed, Gary R. Matsueda, Edgar Haber
-
Patent number: 5357042Abstract: Peptides comprising fibrin-specific epitopic sequences are used to prepare hybridoma cell lines producing antifibrin-specific monoclonal antibodies substantially devoid of fibrinogen-cross-reactivity obtained by somatic cell fusion. The antibodies are useful for the in vivo and in vitro detection of thrombi and fibrin deposits.Type: GrantFiled: August 24, 1992Date of Patent: October 18, 1994Assignee: The General Hospital CorporationInventors: Gary R. Matsueda, Edgar Haber, Kwan Hui
-
Patent number: 5256413Abstract: Disclosed is a method for the in vivo lysis of a thrombus in a host by administration of a conjugate consisting of a monoclonal antibody specific for fibrin coupled to a plasminogen activator such as tissue plasminogen activator, urokinase or streptokinase.Type: GrantFiled: September 15, 1992Date of Patent: October 26, 1993Assignee: The General Hospital CorporationInventors: Edgar Haber, Gary R. Matsueda
-
Patent number: 5116613Abstract: A thrombolytic product comprising a fibrin-specific antibody substantially devoid of fibrinogen cross-reactivity coupled to a thrombolytic agent.Type: GrantFiled: January 8, 1985Date of Patent: May 26, 1992Assignee: The General Hospital CorporationInventors: Edgar Haber, Gary R. Matsueda
-
Patent number: 4927916Abstract: Peptides comprising fibrin-specific epitopic sequences are used to prepare hybridoma cell lines producing antifibrin-specific monoclonal antibodies substantially devoid of fibrinogen-cross-reactivity obtained by somatic cell fusion. The antibodies are useful for the in vivo and in vitro detection of thrombi and fibrin deposits.Type: GrantFiled: January 30, 1986Date of Patent: May 22, 1990Assignee: The General Hospital CorporationInventors: Gary R. Matsueda, Edgar Haber, Kwan Hui
-
Patent number: 4916070Abstract: The invention relates to a method of screening for fibrin clot-specific monoclonal antibodies and to the monoclonal antibodies screened by this method. The invention also relates to immundiagnostic and immunotherapeutic applications of the screened fibrin clot-specific monoclonal antibodies.Type: GrantFiled: April 14, 1986Date of Patent: April 10, 1990Assignee: The General Hospital CorporationInventors: Gary R. Matsueda, Edgar Haber
-
Patent number: 4355023Abstract: Immunologically active rabbit IgG antibody fragment compositions are produced by isolating the anti-light variable chain of rabbit IgG and/or the anti-heavy variable chain of rabbit IgG and combining them with each other or with the complementary heavy or light chain of rabbit IgG.Type: GrantFiled: September 30, 1980Date of Patent: October 19, 1982Assignee: The Massachusetts General HospitalInventors: Paul H. Ehrlich, Gary R. Matsueda, Michael N. Margolies, Edgar Haber
-
Patent number: 3954709Abstract: The phenylethyl group, ##SPC1##In polymer carriers for the synthesis of peptides and peptide amides, particularly polymer carriers such as styrene-1% divinyl benzene polymers for use in solid phase peptide synthesis.The invention described herein was made in the course of work under a grant or award from the Department of Health, Education and Welfare.Type: GrantFiled: May 29, 1973Date of Patent: May 4, 1976Assignee: The Regents of the University of ColoradoInventors: John M. Stewart, Gary R. Matsueda